Safety and effectiveness of daily teriparatide in a prospective observational study in patients with osteoporosis at high risk of fracture in Japan: final report

References

• JohnellOKanisJAAn estimate of the worldwide prevalence, mortality and disability associated with hip fractureOsteoporos Int2004151189790215490120
   PubMed Web of Science ®Google Scholar
• NazrunASTzarMNMokhtarSAMohamedINA systematic review of the outcomes of osteoporotic fracture patients after hospital discharge: morbidity, subsequent fractures, and mortalityTher Clin Risk Manag20141093794825429224
   PubMed Web of Science ®Google Scholar
• JohnellOKanisJEpidemiology of osteoporotic fracturesOsteoporos Int200516Suppl 2S3S715365697
   PubMed Web of Science ®Google Scholar
• HernlundESvedbomAIvergardMOsteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA)Arch Osteoporos2013813624113837
   PubMed Web of Science ®Google Scholar
• OrimoHNakamuraTHosoiTJapanese 2011 guidelines for prevention and treatment of osteoporosis – executive summaryArch Osteoporos2012732023203733
   PubMedGoogle Scholar
• YoshimuraNMurakiSOkaHPrevalence of knee osteoarthritis, lumbar spondylosis, and osteoporosis in Japanese men and women: the research on osteoarthritis/osteoporosis against disability studyJ Bone Miner Metab200927562062819568689
   PubMed Web of Science ®Google Scholar
• HaginoHFeatures of limb fractures: a review of epidemiology from a Japanese perspectiveJ Bone Miner Metab200725526126517704990
   PubMed Web of Science ®Google Scholar
• Forteo^® (teriparatide [rDNA origin] injection) [prescribing information]Kobe, JapanEli Lilly Japan K.K.2014
   Google Scholar
• HodsmanABBauerDCDempsterDWParathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its useEndocr Rev200526568870315769903
   PubMed Web of Science ®Google Scholar
• KregeJHWanXTeriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosisBone201250116116422036910
   PubMed Web of Science ®Google Scholar
• KurlandESCosmanFMcMahonDJRosenCJLindsayRBilezikianJPParathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markersJ Clin Endocrinol Metab20008593069307610999788
   PubMed Web of Science ®Google Scholar
• NeerRMArnaudCDZanchettaJREffect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosisN Engl J Med2001344191434144111346808
   PubMed Web of Science ®Google Scholar
• Fahrleitner-PammerALangdahlBLMarinFFracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS)Osteoporos Int201122102709271921113576
   PubMed Web of Science ®Google Scholar
• WalshJBLemsWFKarrasDEffectiveness of teriparatide in women over 75 years of age with severe osteoporosis: 36-month results from the European Forsteo Observational Study (EFOS)Calcif Tissue Int201290537338322466444
   PubMed Web of Science ®Google Scholar
• MiyauchiAMatsumotoTSugimotoTTsujimotoMWarnerMRNakamuraTEffects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phasesBone201047349350220580870
   PubMed Web of Science ®Google Scholar
• TsujimotoMUenakaKIwataAHigashiuchiYSowaHEffects of teriparatide in Japanese and non-Japanese populations: bridging findings on pharmacokinetics and efficacyJ Bone Miner Metab201230332633721938381
   PubMed Web of Science ®Google Scholar
• YamamotoTTaketsunaMGuoXSatoMSowaHThe safety and effectiveness profile of daily teriparatide in a prospective observational study in Japanese patients with osteoporosis at high risk for fracture: interim reportJ Bone Miner Metab201432669970824368586
   PubMed Web of Science ®Google Scholar
• OrimoHHayashiYFukunagaMOsteoporosis Diagnostic Criteria Review Committee: Japanese Society for Bone and Mineral ResearchDiagnostic criteria for primary osteoporosis: year 2000 revisionJ Bone Miner Metab200119633133711685647
   PubMed Web of Science ®Google Scholar
• WareJEKosinskiMDeweyJEGandekBHow to Score and Interpret Single-Item Health Status Measures: a Manual for Users of the SF-8 Health SurveyLincoln, RIQuality Metric Inc2001
   Google Scholar
• ArdenNKEarlSFisherDJCooperCCarruthersSGoaterMPersistence with teriparatide in patients with osteoporosis: the UK experienceOsteoporos Int200617111626162916823543
   PubMed Web of Science ®Google Scholar
• LangdahlBLRajzbaumGJakobFReduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS)Calcif Tissue Int200985648449319823760
   PubMed Web of Science ®Google Scholar
• TanakaISatoMSugiharaTAdherence and persistence with once-daily teriparatide in Japan: a retrospective, prescription database, cohort studyJ Osteoporos2013201365421824455412
   PubMedGoogle Scholar
• YuSBurgeRTFosterSAGelwicksSMeadowsESThe impact of teriparatide adherence and persistence on fracture outcomesOsteoporos Int20122331103111322159748
   PubMed Web of Science ®Google Scholar
• TamiyaNNoguchiHNishiAPopulation ageing and wellbeing: lessons from Japan’s long-term care insurance policyLancet201137897971183119221885099
   PubMed Web of Science ®Google Scholar
• MiyauchiAMatsumotoTShigetaHTsujimotoMThiebaudDNakamuraTEffect of teriparatide on bone mineral density and biochemical markers in Japanese women with postmenopausal osteoporosis: a 6-month dose-response studyJ Bone Miner Metab200826662463418979163
   PubMed Web of Science ®Google Scholar
• BoonenSMarinFMellstromDSafety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspectiveJ Am Geriatr Soc200654578278916696744
   PubMed Web of Science ®Google Scholar
• Obermayer-PietschBMMarinFMcCloskeyEVEUROFORS InvestigatorsEffects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatmentJ Bone Miner Res200823101591160018505369
   PubMed Web of Science ®Google Scholar
• AndrewsEBGilsenanAWMidkiffKThe US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 yearsJ Bone Miner Res201227122429243722991313
   PubMed Web of Science ®Google Scholar
• HuybrechtsKFIshakKJCaroJJAssessment of compliance with osteoporosis treatment and its consequences in a managed care populationBone200638692292816330270
   PubMed Web of Science ®Google Scholar
• BriotKRavaudPDargent-MolinaPZylbermanMLiu-LeageSRouxCPersistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experienceOsteoporos Int200920462563018661089
   PubMed Web of Science ®Google Scholar
• RajzbaumGGradosFEvansDLiu-LeageSPettoHAugendre-FerranteBTreatment persistence and changes in fracture risk, back pain, and quality of life amongst patients treated with teriparatide in routine clinical care in France: results from the European Forsteo Observational StudyJoint Bone Spine2014811697523796729
   PubMed Web of Science ®Google Scholar
• BoonenSMarinFObermayer-PietschBEffects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosisJ Clin Endocrinol Metab200893385286018160462
   PubMed Web of Science ®Google Scholar
• EttingerBSan MartinJCransGPavoIDifferential effects of teriparatide on BMD after treatment with raloxifene or alendronateJ Bone Miner Res200419574575115068497
   PubMed Web of Science ®Google Scholar
• CompstonJESkeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structureBone20074061447145217045858
   PubMed Web of Science ®Google Scholar
• TerreniAPezzatiPBiochemical markers in the follow-up of the osteoporotic patientsClin Cases Miner Bone Metab201292808423087715
   PubMedGoogle Scholar
• NiimiRKonoTNishiharaAAn algorithm using the early changes in PINP to predict the future BMD response for patients treated with daily teriparatideOsteoporos Int201425137738423812597
   PubMed Web of Science ®Google Scholar
• TsujimotoMChenPMiyauchiASowaHKregeJHPINP as an aid for monitoring patients treated with teriparatideBone201148479880321168536
   PubMed Web of Science ®Google Scholar
• BlumsohnAMarinFNickelsenTEUROFORS Study GroupEarly changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatideOsteoporos Int20112261935194620938767
   PubMed Web of Science ®Google Scholar
• KregeJHLaneNEHarrisJMMillerPDPINP as a biological response marker during teriparatide treatment for osteoporosisOsteoporos Int20142592159217124599274
   PubMed Web of Science ®Google Scholar
• McClungMRSan MartinJMillerPDOpposite bone remodeling effects of teriparatide and alendronate in increasing bone massArch Intern Med2005165151762176816087825
   PubMed Web of Science ®Google Scholar
• HenriksenKTankoLBQvistPDelmasPDChristiansenCKarsdalMAAssessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseasesOsteoporos Int200718568168517124552
   PubMed Web of Science ®Google Scholar
• LjunggrenOBarrettAStoykovIEffective osteoporosis treatment with teriparatide is associated with enhanced quality of life in postmenopausal women with osteoporosis: the European Forsteo Observational StudyBMC Musculoskelet Disord20131425123968239
   PubMed Web of Science ®Google Scholar
• FosterSAFoleyKAMeadowsESCharacteristics of patients initiating teriparatide for the treatment of osteoporosisOsteoporos Int200819337337717710352
   PubMed Web of Science ®Google Scholar
• LjunggrenOBenhamouCLDekkerJStudy description and baseline characteristics of the population enrolled in a multinational observational study of extended teriparatide use (ExFOS)Curr Med Res Opin20143081607161624720366
   PubMed Web of Science ®Google Scholar
• RajzbaumGJakobFKarrasDCharacterization of patients in the European Forsteo Observational Study (EFOS): postmenopausal women entering teriparatide treatment in a community settingCurr Med Res Opin200824237738418154690
   PubMed Web of Science ®Google Scholar